PAXLOVID

Medical Information
Tunisia
 

This medical information website is intended only for healthcare professionals registered to practice in Tunisia.

Please choose the category that best describes you.

This content is intended only for healthcare professionals registered to practice in Tunisia.

April 5, 2022

Paxlovid (PF-07321332/ritonavir) does not have a Marketing Authorization. It has been granted an Emergency Use Authorization (EUA) by the Tunisia Ministry of Health for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.